George Lau
Overview
Explore the profile of George Lau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C, et al.
Hepatol Int
. 2025 Feb;
PMID: 40016576
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association...
3.
Chen J, Jia J, Zhuang H, Zhang W, Yang J, Tanwandee T, et al.
Hepatol Int
. 2025 Feb;
PMID: 39900677
Background: The Asia-Pacific (AP) region carries a substantial burden of HBV. Affordable HBV treatment is crucial to attain WHO's elimination goal. This study assesses the pricing and affordability of HBV...
4.
Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, et al.
Hepatol Int
. 2024 Nov;
18(6):1661-1683.
PMID: 39570557
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs...
5.
6.
Wiley W, Epitropoulos A, Whitman J, Liang E, Sadri E, Lau G
J Cataract Refract Surg
. 2024 Sep;
50(12):1236-1241.
PMID: 39231627
Purpose: To evaluate the rotational stability and visual performance of the enVista toric intraocular lens (IOL) (MX60ET) in cataract patients with preexisting astigmatism. Setting: 6 U.S. sites. Design: Prospective, multicenter....
7.
Chen J, Jia J, Zhuang H, Wen Y, Sarin S, Omata M, et al.
Hepatol Int
. 2024 Aug;
18(5):1431-1433.
PMID: 39190245
No abstract available.
8.
Li Z, Chen D, Jia Y, He Q, Cui L, Du F, et al.
Front Cell Infect Microbiol
. 2024 Aug;
14:1413589.
PMID: 39170987
Background: About 20% of on-treatment patients with chronic hepatitis B (CHB) experienced low-level viraemia (LLV), which is associated with persistent low-grade inflammation, fibrosis progression, and increased risk of hepatocellular carcinoma....
9.
Lau G, Abou-Alfa G, Cheng A, Sukeepaisarnjaroen W, Dao T, Kang Y, et al.
J Hepatol
. 2024 Aug;
82(2):258-267.
PMID: 39089633
Background & Aims: In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was non-inferior...
10.
Lv G, Ji D, Yu L, Chen H, Chen J, He M, et al.
Hepatol Int
. 2024 Jul;
18(5):1459-1471.
PMID: 38965190
Background And Aims: The risk of hepatocellular carcinoma (HCC) occurrence following antiviral therapy in patients with chronic hepatitis C (CHC) remains unclear. The current study aims to compare: (1) the...